Want to see IN:SUVEN full AI Analyst Report?
SUVEN Stock Chart & Stats
₹165.00
₹14.56(11.52%)
At close: 4:00 PM EST
₹165.00
₹14.56(11.52%)
Day’s Range― - ―
52-Week Range₹124.35 - ₹402.90
Previous CloseN/A
Volume2.87M
Average Volume (3M)61.02K
Market Cap
₹98.94B
Enterprise Value₹30.02K
Total Cash (Recent Filing)₹5.18B
Total Debt (Recent Filing)₹166.94M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield11.14%
Share Statistics
EPS (TTM)-12.41
Shares Outstanding282,562,680
10 Day Avg. Volume49,208
30 Day Avg. Volume61,015
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)5.07
Price to Sales (P/S)421.72
P/FCF Ratio-9.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
R&D-driven Business Model And IP GenerationSuven's core model centers on drug discovery and generating chemical entities/IP in CNS areas. That capability is a durable strategic asset: owning discovery expertise and IP enables licensing, partnerships, or milestone-driven cash inflows over multiple years if candidates progress, supporting long-term optionality.
Low Leverage And Balance-sheet FlexibilityMinimal debt reduces near-term default risk and preserves strategic flexibility to fund R&D or pursue partnerships. Low leverage gives management optionality to raise capital at opportune times, limit interest burden, and prioritize project funding decisions—advantages that persist across multiple quarters.
Top-line Recovery In Latest PeriodA meaningful revenue pickup in FY2026 suggests renewed commercial traction or project progress. If sustained, higher sales allow better fixed-cost absorption and create a platform for margin recovery and scaling R&D investments, improving long-term viability compared with continued stagnation.
Bears Say
Persistent Operating And Net LossesRecurring operating and net losses indicate the business is not yet generating sustainable profits. Over months this erodes retained capital, forces reliance on external funding or dilution, and constrains reinvestment in development programs—limiting ability to convert discovery capabilities into long-term shareholder value.
Consistent Negative Operating And Free Cash FlowChronic negative operating and free cash flow means the company cannot self-fund its R&D and operations. Accelerating cash burn increases the probability of future equity raises or partnership dependencies, which can dilute returns and shift strategic priorities away from optimal long-term projects.
Negative Returns And Volatile Equity MetricsSustained negative ROE shows poor capital productivity and an inability to generate returns from invested equity. Combined with material year-to-year swings in equity and assets, this creates uncertainty around capital efficiency and future profitability, weakening structural long-term return prospects.
Suven Life Sciences Limited News
SUVEN FAQ
What was Suven Life Sciences Limited’s price range in the past 12 months?
Suven Life Sciences Limited lowest stock price was ₹124.35 and its highest was ₹402.90 in the past 12 months.
What is Suven Life Sciences Limited’s market cap?
Suven Life Sciences Limited’s market cap is ₹98.94B.
When is Suven Life Sciences Limited’s upcoming earnings report date?
Suven Life Sciences Limited’s upcoming earnings report date is Nov 14, 2026 which is in 55 days.
How were Suven Life Sciences Limited’s earnings last quarter?
Suven Life Sciences Limited released its earnings results on Aug 06, 2026. The company reported -₹4.516 earnings per share for the quarter.
Is Suven Life Sciences Limited overvalued?
According to Wall Street analysts Suven Life Sciences Limited’s price is currently Overvalued.
Does Suven Life Sciences Limited pay dividends?
Suven Life Sciences Limited pays a Annually dividend of ₹1.382 which represents an annual dividend yield of 11.14%. See more information on Suven Life Sciences Limited dividends here
What is Suven Life Sciences Limited’s EPS estimate?
Suven Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suven Life Sciences Limited have?
Suven Life Sciences Limited has 282,562,680 shares outstanding.
What happened to Suven Life Sciences Limited’s price movement after its last earnings report?
Suven Life Sciences Limited reported an EPS of -₹4.516 in its last earnings report. Following the earnings report the stock price went down -2.746%.
Which hedge fund is a major shareholder of Suven Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:SUVEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suven Life Sciences Limited
Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative conditions across key markets including India, the United States, Europe, and other international territories. The company's core activities revolve around the discovery and subsequent development of new chemical entities (NCEs) specifically targeting disorders of the central nervous system (CNS). Among its promising pipeline assets are SUVN-502, intended for Alzheimer's disease and associated neuropsychiatric manifestations; SUVN-G3031, a potent and selective inverse agonist of the histamine H3 receptor, aimed at sleep and cognitive impairments; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist designed to alleviate depressive disorders. Further advancing its portfolio, Suven is also working on SUVN-D4010, a potent, selective, orally bioavailable, and brain-penetrant partial agonist of the 5-HT4 receptor for cognitive dysfunctions; SUVN-I6107, addressing cognitive issues and schizophrenia; SUVN-M8036 for various psychiatric ailments; and SUVN-D1044, targeting gastrointestinal conditions. Established in 1989, the company is based in Hyderabad, India. It adopted its current name, Suven Life Sciences Limited, in 2003, having previously operated as Suven Pharmaceuticals Pvt. Ltd. Jasti Property and Equity Holdings Private Limited holds a controlling interest in Suven Life Sciences Limited, making it a subsidiary.
Technical Analysis
Divi's Laboratories Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Sun Pharma Advanced Research Co. Ltd.
―